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NLRP3 inflammasome deficiency 
attenuates metabolic disturbances 
involving alterations in the gut 
microbial profile in mice exposed 
to high fat diet
Marina Sokolova1,2, Kuan Yang1,2, Simen H. Hansen1,2,3, Mieke C. Louwe1, 
Martin Kummen1,2,3,4, Johannes E. R. Hov1,2,3,5, Ivar Sjaastad6,7, Rolf K. Berge8,9, 
Bente Halvorsen1,2, Pål Aukrust1,2,10, Arne Yndestad1,2 & Trine Ranheim1,2*
Obesity-related diseases (e.g. type 2 diabetes mellitus and cardiovascular disorders) represent an 
increasing health problem worldwide. NLRP3 inflammasome activation may underlie obesity-induced 
inflammation and insulin resistance, and NLRP3 deficient mice exposed to high fat diet (HFD) appear 
to be protected from left ventricle (LV) concentric remodeling. Herein, we investigated if these 
beneficial effects were associated with alterations in plasma metabolites, using metabolomic and 
lipidomic analysis, and gut microbiota composition, using 16S rRNA sequencing of cecum content, 
comparing NLRP3 deficient and wild type (WT) mice on HFD and control diet. Obese NLRP3 deficient 
mice had lower systemic ceramide levels, potentially resulting attenuating inflammation, altered 
hepatic expression of fatty acids (FA) with lower mono-saturated FA and higher polyunsaturated 
FA levels, potentially counteracting development of liver steatosis, downregulated myocardial 
energy metabolism as assessed by proteomic analyses of LV heart tissue, and different levels of 
bile acids as compared with WT mice. These changes were accompanied by an altered composition 
of gut microbiota associated with decreased systemic levels of tri-methylamine-N-oxide and 
lipopolysaccharide, potentially inducing attenuating systemic inflammation and beneficial effects 
on lipid metabolism. Our findings support a role of NLRP3 inflammasome in the interface between 
metabolic and inflammatory stress, involving an altered gut microbiota composition.
Obesity is a global pandemic leading to increased morbidity and  mortality1–4. Thus, obesity-related diseases, such 
as insulin resistance and type 2 diabetes mellitus (T2DM), cardiovascular disorders (CVD) and non-alcoholic 
fatty liver disease (NAFLD) represent an increasing health problem worldwide. However, the mechanisms by 
which obesity contributes to these disorders are still not fully  clarified5–8.
Inflammasomes are multiprotein inflammatory platforms that induce caspase-1 activation and subsequently 
release of interleukin (IL)-1β and IL-18 representing prototypical inflammatory  cytokines9. The NOD-like recep-
tor family pyrin domain-containing 3 (NLRP3) inflammasome responds to numerous physically and chemically 
diverse stimuli such as potassium efflux, reactive oxygen species (ROS), extracellular adenosine triphosphate 
(ATP), and various crystals including cholesterol  crystals10. We and others have suggested that NLRP3 inflam-
masome may be a missing link between obesity and cardiovascular and metabolic disorders, but the molecular 
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pathways that mediate these interactions are intensively debated and remain to be fully  defined11–14. Studies 
suggest a significant role of NLRP3 inflammasome in the initiation and progression of metaflammation (i.e., met-
abolically-induced inflammation) and related diseases, such as obesity, T2DM, NAFLD, and  atherosclerosis15–17. 
NAFLD is the most common liver disease and there are several studies suggesting that NLRP3 inflammasome, 
bridging inflammation and fibrosis, could play an important role and potentially representing novel targets for 
therapy in this  disorder18–20. In support of this hypothesis, we have demonstrated that NLRP3 inflammasome is 
functional in the heart with the potential to regulate cardiac function and cell  death21. Moreover, we have recently 
showed that NLRP3 deficient mice on high fat diet (HFD) were protected from adverse myocardial remodeling, 
and the absence of NLRP3 inflammasome components was shown to suppress obesity-induced hepatic steatosis 
and systemic inflammation and seemed also to have beneficial effects on glucose  metabolism22. Long-term expo-
sure to HFD is a relevant model for examining the effects of an unhealthy diet and obesity on the myocardium, 
and will reflect the situation in patients with moderate obesity, T2DM, liver steatosis and hyperlipidemia.
Several metabolic pathways may mediate the harmful effect of obesity on related cardiovascular and metabolic 
disorders. Thus, sphingolipids are emerging as bioactive lipids that play key roles in the regulation of cell growth, 
viability, differentiation, and senescence, in addition to their traditional roles in the membrane  structure23. 
Moreover, bile acids are cholesterol-derived metabolites that facilitate digestion and absorption of dietary lipids. 
Bile acids have also emerged as pivotal signaling molecules controlling glucose, lipid, and energy metabolism, 
as well as  inflammation24. Furthermore, conjugation of bile acids with glycine or taurine increases their hydro-
phobicity and decreases their membrane permeability, which leads to cytotoxicity, and these mechanisms have 
been implicated in metabolic disturbances during  obesity25. Several studies during recent years have focused on 
the role of gut microbiota in mediating metabolic and inflammatory disturbances. This bacterial community in 
the gut plays an essential role in regulating the bile acid pool by the formation of unconjugated and secondary 
bile  acids26. Moreover, through gut leakage mechanisms, bacterial products like lipopolysaccharide (LPS) may 
activate macrophages in abdominal fat tissue contributing to a state of metabolic induced inflammation in obese 
 patients26. Indeed, changes in the intestinal microbiota have been described in obese patients and in those with 
T2DM and atherosclerotic  disorders27,28. The NLRP3 inflammasome could clearly be involved in several of these 
processes, in particular in relation to LPS-mediated inflammation in abdominal fat tissues, but these issues are 
far from well understood.
The present study is a follow-up on our previous article, Sokolova et al.22, where we have shown that NLRP3 
deficiency in mice on HFD has a beneficial effect on obesity-induced myocardial remodeling and dysfunction 
with attenuated infiltration of Mac-2 positive cells, insulin sensitivity, systemic inflammation (decreased levels 
of IL-18 and tumor necrosis factor), and liver steatosis. In this follow-up study we investigated if these beneficial 
effects were associated with alterations in plasma metabolites using a global metabolomic approach and gut 
microbiota composition, comparing NLRP3 deficient and wild type (WT) mice on HFD. For comparison we 
also examined corresponding changes in NLRP3 deficient and WT mice on a control diet.
Results
Global biochemical profiles were determined in mouse plasma collected from WT and NLRP3 deficient mice 
fed either control diet or HFD. NLRP3 deficiency had profound effects on the plasma metabolome of mice on 
both control diet and HFD, and with some exceptions, the most striking effects was seen during HFD. There 
were particularly three categories of metabolites/pathways that were affected: complex lipids, energy metabolism, 
and cholesterol and bile acid metabolism.
Complex lipids: ceramides. In WT mice HFD-induced obesity was associated with a strong increase in all 
of the complex lipids evaluated (i.e. phospholipids, sphingolipids, and neutral complex lipids; free FAs excluded) 
(Table 1). Notably, these effects were markedly less apparent in obese NLRP3 deficient mice, showing lower 
levels of most phospholipids, sphingolipids, and cholesterol esters as compared with obese WT mice. Interest-
ingly, it has recently been demonstrated that obesity-related molecules, such as ceramides, can also serve as 
damage-associated molecular patterns (DAMPs), and are implicated in the recognition of metabolic stress and 
related inflammatory  responses29. Indeed, most of the ceramides species, including short-chain and long-chain 
ceramides e.g. CER14:0, P = 0.0002; CER16:0, P = 0.0000; CER18:0, P = 0.0000; CER18:1, P = 0.0000; CER20:1, 
P = 0.017; CER24:0, P = 0.011; CER24:1, P = 0.0001 and CER26:1, P = 0.0000, were significantly increased in WT 
plasma on HFD as compared with levels in deficient mice. Thus, it seems that NLRP3 deficiency markedly 
attenuated the increase in ceramide species during obesity pointing to a role for ceramides as a mechanism for 
NLRP3-driven inflammation during metabolic stress.
Energy metabolism. Effects on citric acid metabolism. Obesity had little effect on plasma glucose, pyru-
vate, or lactate levels (Table 2). Importantly, however, NLRP3 deficient mice on control diet had higher glucose 
levels compared to the WT mice (P = 0.05), and as for lactate, NLRP3 deficient mice had higher levels indepen-
dently of the diet (P = 0.02, CD; P = 0.01, HFD). This could suggest that lack of NLRP3 may increase glycolysis or 
the activity of lactate dehydrogenase that mediates the formation of pyruvate to lactate, or a combination thereof.
Pyruvate links glucose metabolism to the Krebs cycle via the generation of acetyl CoA. Herein we found 
lower levels of almost all Krebs cycle intermediates in the NLRP3 deficient mice on control diet compared to 
WT mice on the same diet. These differences seemed to disappear when both groups were on HFD (Table 2). 
Thus, it appears that NLRP3 deficiency influence lactate formation and Krebs cycle metabolites with the most 
prominent findings during control diet.
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Effects on fatty acid metabolism. FA metabolism can also provide acetyl CoA for energy generation. Herein, 
the plasma levels of many medium and long chain FA, as well as polyunsaturated FAs (PUFA)s, were lower in 
obese NLRP3 deficient mice than in obese WT mice (Fig. 1A). These findings could be a result of decreased food 
intake, but this was not evident when evaluating the circulating markers of food intake from the metabolomic 
dataset (e.g. gluconate, 2-keto-3-deoxy-gluconate, stachydrine and homostachydrine; which are markers of food 
additive, viscosifier, plants and whole grain, respectively) (Supplementary Fig. S1B). In addition, the food intake 
was calculated in week 21, showing no difference between the genotypes (Supplementary Fig. S1A). In line with 
this, we have previously  shown22, using the same model as in the present study, a significant separation of body 
weight between mice on HFD and control diet from week 9, determining the initial moment of obesity. Notably, 
although both mouse genotypes showed increased weight during HFD, WT mice gained significantly more 
Table 1.  HFD resulted in strong alterations in all of the complex lipids (free fatty acids excluded) in plasma 
in the WT mice. WT and  NLRP3−/− male mice were exposed to high fat diet (HFD; 60 cal% fat) or control 
diet (CD) for 52 weeks. Table represents fold of change between  NLRP3−/− and WT mice on CD or HFD; and 
between HFD and CD in WT or  NLRP3−/− mice. Metabolite levels that increase in response to the diet are bold 
(P ≤ 0.05), and lipid levels that decrease are italics (P ≤ 0.05). [WT: CD, n = 4; HFD, n = 4 and  NLRP3−/−: CD, 




CD HFD WT NLRP3−/−
Phospholipid
Phosphatidylcholines 1.25 0.62 3.10 1.53
Lysophosphatidylcholines 1.21 0.72 2.00 1.18
Phosphatidylethanolamines 0.95 0.72 1.98 1.49
Lysophosphatidylethano-
lamines 0.99 0.78 1.87 1.47
Phosphatidylinositols 1.06 0.75 2.00 1.41
Sphingolipid
Ceramides 1.35 0.57 3.22 1.36
Dihydroceramides 1.09 0.80 1.46 1.07
Hexosylceramides 2.16 0.63 3.31 0.97
Lactosylceramides 1.29 0.92 1.48 1.05
Sphingomyelins 1.70 0.63 3.70 1.38
Neutral complex lipids
Free fatty acids 0.89 0.87 1.05 1.03
Cholesteryl esters 1.52 0.66 2.85 1.25
Diacylglycerols 1.46 0.86 1.72 1.01
Triacylglycerols 1.75 0.86 2.10 1.04
Monoacylglycerols 1.44 0.98 1.50 1.02
Table 2.  Lower levels of Krebs cycle intermediates in the plasma from  NLRP3−/− mice on control diet. WT and 
 NLRP3−/− male mice were exposed to high fat diet (HFD; 60 cal% fat) or control diet (CD) for 52 weeks. Table 
represents fold of change in Krebs cycle intermediates between  NLRP3−/− and WT mice on CD or HFD; and 
between HFD and CD in WT or  NLRP3−/− mice. Metabolite levels that increase in response to the diet are bold 
(P ≤ 0.05), and lipid levels that decrease are italics (P ≤ 0.05). [WT: CD, n = 4; HFD, n = 4 and  NLRP3−/−: CD, 




CD HFD WT NLRP3−/−
Glycolysis, gluconeogenesis, 
and pyruvate metabolism
Glucose 1.29 0.94 1.14 0.83
Pyruvate 1.36 1.42 1.00 1.05
Lactate 1.50 1.57 0.95 1.00
Krebs cycle intermediate
Citrate 0.63 0.88 0.90 1.26
Aconitate 0.63 0.65 1.26 1.30
Alpha-ketoglutarate 0.35 0.71 0.69 1.41
Succinate 1.38 1.30 0.73 0.69
Fumarate 0.38 1.16 0.30 0.89
Malate 0.45 1.07 0.36 0.85
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weight than the NLRP3 inflammasome deficient mice. In contrast, no differences in weight gain between the 
two genotypes during control  diet22. Furthermore, liver weights were markedly elevated in WT mice compared 
with NLRP3 deficient mice during HFD, but not during control  diet22. The reduced FFA levels could also be 
an indication of an effect of NLRP3 on FFA synthesis or metabolism in the liver as the liver FAs in the NLRP3 
deficient mice on HFD were significantly reduced compared to WT (P = 0.01) (Fig. 1B). Additionally, liver FA 
composition (weight %) showed that whereas the monounsaturated FAs (MUFAs) were decreased in NLRP3 
deficient mice on HFD compared to WT mice, the PUFAs (both n-3 and n-6) were increased in NLRP3 deficient 
mice (Fig. 1C). Thus, whereas HFD induced a clear pattern with decreased MUFA and increased PUFA in the 
liver of NLRP3 deficient mice on HFD, the pattern in plasma was less obvious with a decrease in several FA even 
during control diet.
We also investigated immune cell infiltration in the liver by staining for Mac-2, a macrophage surface marker, 
and we observed a significant increase in Mac-2 positive staining in the liver in WT mice on HFD compared to 
NLRP3 deficient mice on the same diet (Supplementary Fig. S2A,B).
Figure 1.  HFD resulted in higher levels of fatty acids in plasma and liver. WT and  NLRP3−/− male mice were 
exposed to high fat diet (HFD; 60 cal% fat) or control diet (CD) for 52 weeks. (A) Individual histograms of 
representative plasma fatty acids. Myristoleic acid #P = 0.035 WT HFD vs. WT CD, *P = 0.0006  NLRP3−/− CD vs. 
WT CD, *P = 0.024  NLRP3−/− HFD vs. WT HFD; Palmitoleic acid #P = 0.000 WT HFD vs. WT CD, *P = 0.0001 
 NLRP3−/− CD vs. WT CD, *P = 0.003  NLRP3−/− HFD vs. WT HFD; Adrenic acid #P = 0.003 WT HFD vs. WT 
CD, *P = 0.04  NLRP3−/− HFD vs. WT HFD, #P = 0.048  NLRP3−/− HFD vs.  NLRP3−/− CD; Docosapentaenoic acid 
*P = 0.034  NLRP3−/− CD vs. WT CD. [WT: CD, n = 4; HFD, n = 4 and  NLRP3−/−: CD, n = 4; HFD, n = 4]. (B) Total 
liver fatty acids. #P = 0.0001 WT HFD vs. WT CD, *P = 0.0001  NLRP3−/− HFD vs. WT HFD. [WT: CD, n = 11; 
HFD, n = 10 and  NLRP3−/−: CD, n = 7; HFD, n = 7]. Data are means ± SEM. (C) Stack bars of liver fatty acid 
composition (weight %). SFA *P = 0.0003  NLRP3−/− CD vs. WT CD, *P = 0.0001  NLRP3−/− HFD vs. WT HFD; 
MUFA #P = 0.008 WT HFD vs. WT CD, *P = 0.0000  NLRP3−/− HFD vs. WT HFD; PUFA n-3 #P = 0.0000 WT 
HFD vs. WT CD, *P = 0.0000  NLRP3−/− HFD vs. WT HFD; and PUFA n-6 *P < 0.0000  NLRP3−/− HFD vs. WT 
HFD, #P = 0.008  NLRP3−/− HFD vs.  NLRP3−/− CD. [WT: CD, n = 11; HFD, n = 10 and  NLRP3−/−: CD, n = 7; HFD, 
n = 7]. * representing significant differences between the two genotypes  (NLRP3−/− and WT) fed either HFD or 
control diet; and # representing significant differences between HFD and control diet within one genotype, (i.e. 
WT or  NLRP3−/−).
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Cholesterol and bile acid metabolism. Cholesterol plays an important role in bile acid metabolism, and 
in the current study HFD-induced obesity was associated with a marked increase in total cholesterol, but impor-
tantly, this effect was significantly attenuated in obese NLRP3 deficient mice (Fig. 2A; P = 0.006). HFD resulted 
in lower levels of cholate in both genotypes, but notably, this effect was more prominent in NLRP3 deficient 
mice (Fig. 2B). While there was no significant difference in taurine, HFD significantly increased several taurine-
conjugated bile acids (e.g. taurocholate, P = 0.002; taurochenodeoxycholate, P = 0.05; tauro-beta-muricholate, 
P = 0.01; taurodeoxycholate, P = 0.01; and tauroursodeoxycholate, P = 0.001) in the WT mice (Fig. 2B). Strikingly, 
these HFD-induced effects were nearly abrogated in the NLRP3 deficient mice (Fig. 2B). Interestingly, whereas 
there was an increase in bile acids with a higher hydrophobicity during HFD in WT mice, these bile acids 
decreased during HFD in NLRP3 deficient mice (Fig. 2C).
Analysis of the left ventricular tissue during HFD. We have previously reported that NLRP3 defi-
ciency had a beneficial effect on obesity-induced myocardial remodeling and dysfunction in  mice22. To further 
examine the influence of HFD on myocardial remodeling in the two genotypes, we performed mass spectrome-
try-based proteomics of the LV. The ten most significant GO terms identified as major functional gene categories 
disproportionably affected by HFD in WT and NLRP3 deficient mice are illustrated in Fig. 3A,B.
In the “Fatty acid biosynthesis” pathway based on the KEGG “Fatty acid degradation” pathway, six proteins 
were lower in NLRP3 deficient mice on HFD compared to WT mice (P = 0.0016), suggesting that less FA are 
Figure 2.  Changes in plasma cholesterol and bile acid metabolism. WT and  NLRP3−/− male mice were 
exposed to high fat diet (HFD; 60 cal% fat) or control diet (CD) for 52 weeks. (A) Total cholesterol #P = 0.0001 
WT HFD vs. WT CD, #P = 0.04  NLRP3−/− HFD vs.  NLRP3−/− CD, *P = 0.006  NLRP3−/− HFD vs. WT HFD 
diet, *P = 0.02  NLRP3−/− CD vs. WT CD. (B) Table represents fold of change in the amino acid taurine and 
primary—and secondary bile acids between  NLRP3−/− and WT mice on CD or HFD; and between HFD and 
CD in WT or  NLRP3−/− mice. Metabolite levels that increase in response to the diet are colored red (P ≤ 0.05), 
and lipid levels that decrease are colored green (P ≤ 0.05). (C) Hydrophobicity of bile acids. Cholate (CA) 
#P = 0.01 WT HFD vs. WT CD, #P = 0.0001  NLRP3−/− HFD vs.  NLRP3−/− CD, *P = 0.03  NLRP3−/− HFD vs. 
WT HFD. Chenodeoxycholate (CDCA) #P = 0.0000 WT HFD vs. WT CD, *P = 0.0002  NLRP3−/− CD vs. WT 
CD. Deoxycholate (DCA) *P = 0.02  NLRP3−/− HFD vs. WT HFD. [WT: CD, n = 4; HFD, n = 4 and  NLRP3−/−: 
CD, n = 4; HFD, n = 4]; each biochemical is rescaled to set the median equal to 1. Data are means ± SEM. * 
representing significant differences between the two genotypes  (NLRP3−/− and WT) fed either HFD or control 
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used as fuel for oxidation in NLRP3 deficient mice on HFD (Fig. 4A). Interestingly, six proteins involved in the 
Krebs cycle also showed significantly reduced levels (P = 0.0002), and lactate dehydrogenase was lower in the 
NLRP3 deficient mice on HFD (P = 0.0016) (Fig. 4B) indicating that NLRP3 deficiency may markedly influence 
the glycolytic pathway, lactate dehydrogenase activity, and the Krebs cycle intermediates also within the myo-
cardium. Altogether, these data indicate lower overall energy metabolism in the heart in obese NLRP3 deficient 
mice as compared with WT mice. This altered energy metabolism within the myocardium in NLRP3 deficient 
mice on HFD is also illustrated by heatmaps (Fig. 4C,D). In contrast, mice fed the control diet showed no major 
differences in the protein pattern between the genotypes (Supplementary Fig. S4).
We additionally investigated the ceramide content in the LV tissue from the two mouse strains. Immuno-
fluorescence showed that ceramide was co-localized in both genotypes to the mitochondria especially in the 
endothelial cell-layer surrounding the vessels, visualized with succinate dehydrogenase complex assembly fac-
tor (SDHAF) 2, a mitochondrial complex 2 marker (Fig. 5C). Interestingly, however, in contrast to the plasma 
findings, IHC revealed no difference in the levels of ceramide (Fig. 5A–C) between the genotypes. Arrows are 
drawn to visualize ceramide staining in the endothelial layer (Fig. 5A).
In addition to infiltrating macrophages, NLRP3 inflammasomes within the myocardium could be located in 
endothelial  cells30. To test this in our model we examined the expression of NLRP3 and caspase-1 in myocardial 
endothelial cells in WT mice exposed to HFD or control diet (Supplementary Fig. S3). Immunofluorescence 
showed that the proteins were co-localized in the endothelial cells. WT mice fed a HFD showed a trend towards 
increased expression of NLRP3, but this difference was not statistical significant (P = 0.06). As for caspase-1, the 
localization within endothelial cells was scarce.
Gut microbiota and systemic metabolic disturbances. The gut microbiota has been suggested to 
influence obesity and related metabolic and inflammatory  disturbances31. Finally, we examined the effect of diet 
and genotypes on the microbial profiles in the cecal content. The bacterial composition (beta diversity) was sig-
nificantly different between genotypes and diets in the experimental groups (P = 0.001) (Fig. 6A). Moreover, the 
effect of diet type and genotype on microbial composition (alpha diversity) was determined using the Shannon 
diversity index and Observed operational taxonomic units (OTUs) for microbial composition. Whereas HFD 
induced increase alpha diversity in WT mice, the opposite was seen in NLRP3 deficient mice (Shannon: P = 0.03; 
OTUs: P = 0.004) (Fig. 6B). When exploring which taxa on the phylum levels that drove these compositional dif-
ferences, we found that obese NLRP3 deficient mice had a lower relative abundance of Actinobacteria (P = 0.002) 
Figure 3.  The Gene Ontology biological process categories in left ventricular (LV) tissue. WT and  NLRP3−/− 
male mice were exposed to high fat diet (HFD; 60 cal% fat) or control diet (CD) for 52 weeks. (A) Sector 
diagram of categories of the 10 most significant GO terms. (B) Table of the same GO terms as in (A). Counts 
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and Firmicutes (P = 0.002), and a higher relative abundance of Epsilonbacteraeota (P = 0.004) as compared to 
obese WT mice (Fig. 6C).
Formation of trimethylamine-N-oxide (TMAO) is based on the microbial metabolite trimethylamine (TMA) 
and it has been shown that TMAO levels are associated with low abundance of Bacteroidetes and high abundance 
of Firmicutes, and herein we found that this pattern was seen in the WT mice on control diet and partly on HFD, 
but not in NLRP3 deficient mice (Fig. 7A). Indeed, NLRP3 deficient mice had lower plasma levels of TMAO 
compared to WT mice on HFD (P = 0.009) (Fig. 7B). Moreover, we found that HFD markedly increased the 
systemic LPS levels in WT, and notably, this effect was attenuated in NLRP3 deficient mice (P = 0.036) (Fig. 7C). 
We also showed a significant increase in Bilophila genus of the Proteobacteria phylum in obese WT mice (Sup-
plementary Fig. S5), shown to be associated with taurin-conjugated bile acids, that was elevated in WT mice 
on HFD in our study (Fig. 2B)32. Thus, changes in gut microbiota could through attenuated levels of TMAO, 
LPS, and taurine conjugated bile acid have contributed to beneficial effects of NLRP3 deficiency on myocardial 
remodeling and liver steatosis in these mice on HFD.
Discussion
Obesity and metabolic related cardiac disease is a growing worldwide  concern33,34. The NLRP3 inflammasome 
may represent a link between overnutrition, metabolic stress, inflammation, and development of metabolic and 
cardiovascular diseases, but the molecular mechanisms for these interactions are not fully  elucidated35,36. Herein 
we show several effects of NLRP3 deficiency on control diet, and in particular HFD associated metabolic changes 
in plasma, but also in the liver and within the myocardium. Thus, we show that obese NLRP3 deficient mice had 
lower systemic ceramide levels, a DAMP molecule with potential inflammatory effects, altered hepatic expression 
of FA with lower MUFA and higher PUFA levels, downregulated myocardial energy metabolism and different 
Figure 4.  Altered transcripts in left ventricular (LV) tissue based on the KEGG pathway in the functional 
annotation chart of DAVID database. WT and  NLRP3−/− male mice were exposed to high fat diet (HFD; 
60 cal% fat) or control diet for 52 weeks. (A) Fatty acid biosynthesis. The transcripts are differently expressed 
in  NLRP3−/− vs. WT mice on HFD. P = 0.0016. Acsl1 Acyl-Coenzyme A synthase long chain family member 
1, CPT1/2 Carnitine palmitoyltransferase 1/2, Echs1 Enoyl-Coenzyme A hydratase short chain 1, Hadha 
Hydroxyacyl-Coenzyme A dehydrogenase, Acaa2 Acetyl-Coenzyme A acyltransferase 2. (B) Krebs cycle. 
Transcripts were significantly different regulated in the Krebs cycle in LV in WT and  NLRP3−/− mice on HFD. 
P = 0.0002. Ldh lactate dehydrogenase, Dlat dihydrolipoyl transacetylase, Idh1 isocitrate dehydrogenase 1, 
α-Kgdh alpha-ketoglutarate dehydrogenase, Sdh succinate dehydrogenase. (C) Heatmap presenting differentially 
expressed proteins in the Fatty acid biosynthesis. (D) Heatmap presenting differentially expressed proteins in the 
Krebs cycle. Changes in protein abundance (Z-score) are shown. Proteins were grouped according to metabolic 
pathways. Colors represent either increased (red) or decreased (green) protein abundances. [WT: HFD, n = 5 
and  NLRP3−/−: HFD, n = 4].
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levels of various bile acids as compared with WT mice. Notably, these changes were accompanied by an altered 
composition of gut microbiota associated with decreased systemic levels of TMAO and LPS, suggesting that the 
decreased metabolic and inflammatory stress in NLRP3 deficient mice on HFD were related to changes in gut 
microbiota. We and other have suggested that NLRP3 could be a link between obesity and metabolic and inflam-
matory stress, and our findings herein suggest several molecular pathways that could be related to NLRP3-driven 
inflammation during obesity, including changes in gut microbiota.
It is becoming clear that lipotoxicity and in particular high levels of ceramides could play an important 
role in obesity induced  inflammation37 as well as myocardial remodeling in obese  diabetics38,39. Furthermore, 
altered sphingolipid levels, particularly ceramide and sphingomyelin, seemed to be involved in obesity-induced 
endothelial dysfunction and  atherosclerosis40. Additionally, acylCoA synthase long-chain family member 1 
(Acsl1) involved in ceramide synthesis and  degradation41,42, was significantly altered in LV tissue in WT mice on 
HFD. Based on these studies, interest for the role of sphingolipids in obesity-induced pathobiology is emerging. 
In the present study we showed that NLRP3 deficiency markedly attenuated the increase in ceramide species dur-
ing HFD in plasma indicating downregulation of DAMP signaling that again could influence NLRP3 activation 
through attenuated signal 1 activation, a priming signal indicative of infection or tissue  damage43. However, when 
investigated in the LV tissue, IHC revealed no difference in the levels of ceramide between the genotypes. We have 
previously described the lack of both myocardial inflammation and fibrosis in our model of NLRP3 deficiency 
on  HFD22 compared to  others44,45, and it is tempting to hypothesize that this at least partly could be due to dif-
ferences in cardiac ceramide accumulation. Thus, whereas our findings support a link between NLRP3-driven 
inflammation and ceramide signaling systemically, the role of these pathways within the myocardium could be 
questioned. However, we cannot exclude that NLRP3 inflammasomes modulate obesity-induced effects on the 
Figure 5.  No difference in the level of ceramide in left ventricular (LV) tissue. WT and  NLRP3−/− male 
mice were exposed to high fat diet (HFD; 60 cal% fat) or control diet (CD) for 52 weeks. (A) Representative 
immunohistochemistry images of ceramide stained LV sections. Arrows are drawn to visualize ceramide 
staining in the endothelial cell layer. [WT: CD, n = 5; HFD, n = 5 and  NLRP3−/−: CD, n = 5; HFD, n = 5]. Scale 
bar: 100 µM. (B) Quantification of ceramide positive stained cells. Data are means ± SEM. (C) Representative 
immunofluorescence image of LV section. [WT: CD, n = 5; HFD, n = 5 and  NLRP3−/−: CD, n = 5; HFD, n = 5]. 
Ceramide in red; mitochondria marker in green; nuclei in blue; co-localization in yellow. Scale bar: 10 µM.
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myocardium through the systemic effects of ceramides-induced inflammation. Indeed, synthesis of ceramides 
occurs in all tissues, and this metabolite accumulates within tissues and plasma during metabolic dysfunction, 
dyslipidemia, and inflammation. A number of studies carried on humans, rodents and cell cultures indicate 
participation of tissue and plasma ceramides in obesity and the development of insulin resistance and heart 
 failure46,47. It is therefore possible that ceramides could affect the myocardium through their increased systemic 
levels. Alternatively, similar levels of ceramide in WT versus  NLRP3−/− endothelial cells might be due to a lack of 
local NLRP3 activation within myocardium endothelial cells. However, we found a trend for increased NLPR3 
expression within myocardial endothelial cells in WT mice on HFD as compared with control diet, but these 
issues will have to be further investigated.
NLRP3 deficiency had several effects on energy and FA metabolism. First, plasma palmitoylcarnitine (as well 
as other conjugated acylcarnitines) was reduced in the NLRP3 deficient mice on both HFD and control diet com-
pared to WT mice, and interestingly, increased levels of acylcarnitines have been observed in several metabolic 
and inflammatory conditions like T2DM, obesity and CVD, potentially related to mitochondrial  dysfunction48. 
Second, the reduced levels of palmitoylcarnitine in NLRP3 deficient mice were also seen within the myocardium 
on HFD. In fact, six enzymes, including carnitine palmitoyl transferase (CPT) 1 and 2, were lower in NLRP3 
deficient mice on HFD compared to WT mice, suggesting that less FA are used as fuel for oxidation in NLRP3 
deficient mice on HFD with potentially beneficial effects on the  myocardium49,50. Third, we observed significantly 
Figure 6.  Metagenomic analysis. WT and  NLRP3−/− male mice were exposed to high fat diet (HFD; 60 cal% fat) 
or control diet (CD) for 52 weeks. (A) Non-metric multidimensional scaling (NMDS) plot focus on grouping 
sampled faecal communities with respect to diet and genotype. Datapoints represent individual mouse. The 
contribution of depth and region to MDS1 (primary NMDS axis) and MDS2 (secondary NMDS axis), P = 0.001. 
(B) Alpha diversity plots; Shannon, #P = 0.01 WT HFD vs. WT CD, *P = 0.03  NLRP3−/− HFD vs. WT HFD, 
and Observed OTUs, #P = 0.008  NLRP3−/− HFD vs.  NLRP3−/− CD, *P < 0.004  NLRP3−/− HFD vs. WT HFD. 
(C) Significantly different abundances of multiple bacterial taxa at the phyla level in WT and  NLRP3−/− mice 
on CD or HFD. [WT: CD, n = 8; HFD, n = 6 and  NLRP3−/−: CD, n = 5; HFD, n = 6]. Data are means ± SEM. * 
representing significant differences between the two genotypes  (NLRP3−/− and WT) fed either HFD or control 
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lower level of Krebs cycle intermediates within the myocardium in obese NLRP3 deficient mice. Recent evi-
dence confers a new role for Krebs cycle intermediates as signaling molecules that could ameliorate activation 
of inflammatory  pathways51,52, but the consequences of the disturbed levels of Krebs cycle intermediates in our 
model need to be further elucidated. Finally, whereas the effect of NLRP3 deficiency on the FA composition in 
plasma was unclear, NLRP3 deficiency on HFD show an increase in PUFA and a decrease in MUFA within the 
liver with potential beneficial effects on hepatic inflammation and metabolism.
Bile acids are cholesterol-derived compounds synthesized in the liver, which facilitate the intestinal absorp-
tion of lipids, but also influence metabolic and inflammatory signaling  pathways53. In the current study, HFD 
induced a marked increase in total cholesterol, but importantly, this effect was significantly attenuated in the 
NLRP3 deficient mice. While there was no significant difference in taurine, HFD significantly increased a number 
of taurine-conjugated bile acids in the WT mice, but not in KO mice. Taurine-conjugated bile acids have a wide 
spectrum of effects and with relevance to our study. It is demonstrated that the microbiota-associated metabolites 
taurine shapes the host-microbiome interface by co-modulating NLRP6 inflammasome signaling, epithelial IL-18 
secretion, and downstream anti-microbial peptide  profiles54. Moreover, Jarret et al.55 show that neuron-derived 
IL-18 signaling has profound consequences on the mucosal barrier and invasive bacterial killing. In line with 
this, we have previously shown, using the same model as in the present  study22, that plasma levels of IL-18 were 
significantly elevated in WT mice fed HFD. Given the known association between taurin-conjugated bile acids, 
HFD and the Bilophila genus of the Proteobacteria  phylum32, which we found increased in obese WT mice, it is 
tempting to speculate that this environment could have contributed to the phenotype in these mice. Moreover, 
hydrophobic bile acids have been proven to affect heart rate and its  contraction56, and have been associated with 
Figure 7.  Altered bacteria profiles in gut microbiota. WT and  NLRP3−/− male mice were exposed to high fat 
diet (HFD; 60 cal% fat) or control diet (CD) for 52 weeks. (A) Distinct bacteria profiles in gut microbiota in 
WT and  NLRP3−/− male mice exposed to HFD or CD. Three phyla are shown; Firmicutes, Bacteriodetes and 
Proteobacteria. These phyla are associated to differences in levels of trimethylamine-N-oxide (TMAO). [WT: 
CD, n = 8; HFD, n = 6 and  NLRP3−/−: CD, n = 5; HFD, n = 6]. (B) TMAO #P = 0.008 WT HFD vs. WT CD, 
#P = 0.0009  NLRP3−/− HFD vs.  NLRP3−/− CD, *P = 0.009  NLRP3−/− HFD vs. WT HFD. [WT: CD, n = 4; HFD, 
n = 4 and  NLRP3−/−: CD, n = 4; HFD, n = 4]; each biochemical is rescaled to set the median equal to 1. (C) Plasma 
lipopolysaccaride (LPS) binding protein. *P = 0.036  NLRP3−/− HFD vs. WT HFD. [WT: CD, n = 9; HFD, n = 9 
and  NLRP3−/−: CD, n = 6; HFD, n = 4]. Data are means ± SEM. * representing significant differences between the 
two genotypes  (NLRP3−/− and WT) fed either HFD or control diet; and # representing significant differences 
between HFD and control diet within one genotype, (i.e. WT or  NLRP3−/−).
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cardiac hypertrophy. It has in fact been suggested that bile acids with a higher hydrophobicity have an increased 
dysfunctional effect within the myocardium. Interestingly, whereas there was an increase in bile acids with a 
higher hydrophobicity during HFD in WT mice in our study, these bile acids decreased during HFD in NLRP3 
deficient mice. Although the net effects of altered bile acid composition in NLRP3 deficient mice are at present 
not clear, our findings should warrant further studies on the interaction between bile acids and NLRP3 inflam-
masome in obesity and related disorders.
The relationship between CVD and intestinal microbiota is of great  interest57. Cui et al. found that the compo-
sition of intestinal microbiota in patients with cardiac heart disease and healthy controls differed, particularly in 
the proportions of members of phyla Bacteroidetes and  Firmicutes58. Also, the intestinal microbiota of obese mice 
is characterized by a higher Firmicutes/Bacteriodetes ratio when compared to lean  mice59. Reducing levels of 
bacteria from the Firmicutes and Bacteroidetes phyla may improve insulin sensitivity in mice with diet-induced 
obesity. Herein we show that during HFD WT mice showed increased levels of Bacteroidetes and high abun-
dance of Firmicutes, and this pattern was at least partly reversed by NLRP3 deficiency. Indeed, these changes in 
bacteria composition was accompanied by decreased levels of TMAO and LPS, potentially reflecting decreased 
levels of microbiota-derived TMA and attenuated gut leakage, respectively. Our findings further link altered gut 
microbiota to HFD induced inflammation. Moreover, the fact that this effect was attenuated by NLRP3 deficiency 
suggests that NLRP3 could be part of a missing link between the gut microbiota and systemic metabolic and 
inflammatory disturbances. The elevated levels of LPS, which were attenuated during NLRP3 deficiency, further 
support such a notion. Similarly, intestinal permeability and bacterial translocation are important contributors 
to chronic systemic inflammation and, might represent a continuous inflammatory stimulus capable of immune 
 processes60–62 . These findings could also be relevant for patients with CVD. Elevation in plasma TMAO concen-
trations is associated with an increased risk of CVD in many different patient  cohorts63. Moreover, gut leakage 
mechanisms with increased release of  endotoxins64, such as the observed increase in LPS in the HFD fed WT 
mice, may contribute to the systemic effects of gut microbiota, potentially involving NLRP3 activation. Indeed, 
LPS is a potent activator of NLRP3 inflammasome (signal 1), and it is tempting to hypothesize that the interac-
tion between gut microbiota, NLRP3 inflammasome with the induction of enhanced release of inflammatory 
cytokines like IL-18, LPS and TMAO could be operating in various relevant obesity-related disorders including 
atherosclerosis and obesity induced myocardial remodeling.
The present study has several limitations such as the lack of a positive control group by for example using 
MCC950, which is a potent and selective inhibitor of the NLRP3  inflammasome65. Furthermore, the small 
number of animals included in the global metabolic profiling analysis is another limitation of our study. In addi-
tion, NLRP3 inflammasomes and their components (e.g., NLRP3, caspase-1 and pro-IL-1β) should have been 
more convincingly located within the myocardium by western blotting. Indeed, inflammasome components 
are difficult to evaluate with immunofluorescence at least partly related to the transient expression of some of 
the binding sites for the antibodies that are used for immunofluorescence  staining66. We also lack data from the 
intestinal tract which is important when studying the interaction between gut microbiota and systemic metabolic 
disturbances. Moreover, associations do not necessarily mean any causal relationship, and our study needs more 
mechanistic study to verify our findings.
To conclude, NLRP3 deficiency had profound and various effects on the plasma metabolome of mice on 
both control diet and in particular on HFD. These effects seem at least partly to involve altered composition of 
gut microbiota. Our findings further support a role of NLRP3 inflammasome in interface between metabolic 
and inflammatory stress, and this role seems to involve a complex interaction between fundamental metabolic 
pathway such as energy metabolism, FA regulation and interaction with lipid related molecules, such as cera-
mides and bile acids.
Methods
Mice. C57BL/6J mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). Nlrp3−/− 
(NLRP3 deficient) mice were generated by Millenium Pharmaceuticals (Cambridge, MA, USA), back-bred onto 
the C57BL/6 strain at least seven (Nlrp3−/−) generations before being  used67,68. Mice were housed in an air-
conditioned, temperature-regulated room with a 12/12 h daylight/night cycle with free access to water and food. 
The diet and genetic background are major determinants of gut microbial composition which again could influ-
ence metabolic and inflammatory diseases. To minimize the effects of other factors than genetics in our study, 
including effects on gut microbiota, the mice were co-housed throughout the study. The separate mouse strains 
were littermates, bred from the same parents, raised in the same cage until weaning where 4–6 mice of the same 
strain where co-housed in the same open cages (Eurostandard type III), and all cages were placed in the same 
room in a randomized manner. Obesity was induced by feeding mice a high fat diet (HFD) (D12492), composed 
of 60% fat, 20% protein, and 20% carbohydrate (Research Diets, New Brunswick, NJ, USA) for 52 weeks. Con-
trol mice were fed a low fat standardized control diet, containing 10% fat, 20% protein and 70% carbohydrate 
(D12450B, Research Diets). Body weight was monitored weekly. Food intake was determined at 21 weeks by 
weighing the food and correcting for the amount not eaten, including spillage. The experimental animal protocol 
(FOTS id 4641), was approved by The Norwegian Food and Safety Authority, which is a national governmental 
body that supervises food, plant, fish and animal health, and by the Norwegian Animal Research Committee 
that conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes 
of Health (NIH Publication, 8th Edition, 2011). All animal experiments were performed in accordance with 
relevant guidelines and regulations.
Blood and tissue sampling. Mice were fasted for 4 h and put in deep anaesthesia with a mixture of 4–5% 
isoflurane and  O2. Arterial blood was collected (by a small incision of the carotid artery) into tubes containing 
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50 μl of 0.5 M EDTA. Plasma was prepared by centrifugation at 500 × g for 20 min and 4 °C, snap-frozen in liq-
uid  N2 and stored at − 80 °C. The heart was extirpated and separated into left ventricle (LV) and right ventricle, 
together with lungs and liver, rinsed in saline solution, blotted dry and weighed. A standardized 2 mm slice was 
taken from the LV using a mouse heart slicer matrix (Zivic Instruments, Pittsburgh, PA, USA). The heart slice 
was fixated in 4% formalin and embedded in paraffin. Remaining tissue was snap-frozen in liquid nitrogen and 
stored at − 80 °C22.
Global metabolic profiling. Global biochemical profiles were determined in mouse plasma collected from 
genotypes/treatment groups as below. Plasma from mice that had been fed HFD or control diet for 52 weeks, 
were immediately frozen in liquid nitrogen. Samples (4 per treatment group) were shipped to Metabolon Inc. 
(Durham, NC, USA) https ://www.metab olon.com where they were extracted and prepared for analysis using a 
previously described standard solvent extraction  method69. Also included were several technical replicate sam-
ples created from a homogeneous pool containing a small amount of all study samples. Metabolite profiling 
was provided by Metabolon Inc. using Ultra High Performance Liquid chromatography/Mass Spectrometry/
Mass Spectrometry (UHPLC/MS/MS) and Gas chromatography/Mass Spectrometry (GC/MS). Fractionation 
and derivisation of samples and detection technologies have been reported  previously70,71. The analysis yielded 
a dataset comprising a total of 520 compounds of known identity. Metabolic pathways were visualized using 
the Cytoscape plugin in the MetaboLync Portal https ://porta l.metab olon.com. The y-axis of figures is termed 
“Scaled intensity”, and indicates normalized values in terms of raw area counts. These values are rescaled to set 
the median equal to 1.
Complex lipid panel. Complex Lipid Panel identifies up to 1100 individual lipid species (Metabolon Inc.). 
This platform provides absolute quantitation of 14 lipid classes, including principle phospholipid, sphingolipid 
and neutral lipid classes. It also provides molecular species concentrations and complete fatty acid composition 
of each lipid class, thereby offering unparalleled insight into the lipidome. Lipids are extracted from samples in 
methanol:dichloromethane in the presence of internal standards. The extracts are concentrated under nitrogen 
and reconstituted in 0.25 ml of 10 mM ammonium acetate methanol: dichloromethane (50:50). The extracts are 
transferred to inserts and placed in vials for infusion-MS analysis, performed on a Shimazdu LC with nano PEEk 
tubing and the Sciex SelexIon-5500 QTRAP. The samples are analyzed via both positive and negative mode elec-
trospray. The 5500 QTRAP scan is performed in MRM mode with the total of more than 1100 MRMs. Individual 
lipid species are quantified by taking the peak area ratios of target compounds and their assigned internal stand-
ards, then multiplying by the concentration of internal standard added to the sample. Lipid class concentrations 
are calculated from the sum of all molecular species within a class, and fatty acid compositions are determined 
by calculating the proportion of each class comprised by individual fatty  acids72.
Measurements of total fatty acid (FA) levels and composition in liver. Lipids were extracted from 
livers using a mixture of chloroform and methanol. The extracts were trans-esterified using boron trifluoride 
 (BF3)-methanol. To remove neutral sterols and non-saponifiable material, extracts of FA methyl esters were 
heated in 0.5 M potassium hydroxide (KOH) in ethanol–water solution (9:1). Recovered FAs were re-esterified 
using  BF3-methanol. The methyl esters were quantified by gas chromatography as previously  described73.
Proteomic analysis. LV tissues of four to five biological replicates were used for proteome  analysis74. The 
total cell protein was extracted by T-PER Mammalian Protein Extraction Reagent containing Halt Protease and 
Phosphatase Inhibitor (Thermo Fisher Scientific, Waltham, MA, USA) and homogenized. The samples were 
transferred to Eppendorf tubes and centrifuged at 14,000 × g 10 min 4 °C. The supernatants were then trans-
ferred to new Eppendorf tubes, and the protein concentration was determined by Pierce BCA Protein Assay Kit 
(Thermo Fisher Scientific).
The precipitated proteins were dissolved with 6 M urea in 100 mM ammonium bicarbonate, reduced with 
dithiothreitol (10 mg/ml) and alkylated with iodoacetamide (25 mg/ml). For total proteome analysis, the proteins 
were in-solution digested by diluting the urea concentration to 1 M followed by digestion with trypsin overnight 
at 37 °C. The resulting peptides were desalted and concentrated before mass spectrometry by the STAGE-TIP 
method using a C18 resin disk (3 M Empore). Each peptide mixture was analyzed by a nEASY-LC coupled to 
QExactive Plus (Thermo Electron, Bremen, Germany) with EASY Spray PepMap RSLC column (C18, 2 µl, 
100 Å, 75 µm × 50 cm). For proteome samples, 120 min LC separation gradient was used. The resulting MS raw 
files were submitted to the MaxQuant software version 1.6.1.0 for protein identification and label-free quan-
tification (LFQ). Carbamidomethyl (C) was set as a fixed modification and acetyl (protein N-term), carbamyl 
(N-term) and oxidation (M) were set as variable modifications. First search peptide tolerance of 20 ppm and main 
search error 4.5 ppm were used. Trypsin without proline restriction enzyme option was used, with two allowed 
miscleavages. The minimal unique + razor peptides number was set to 1, and the allowed false discovery rate 
(FDR) was 0.01 (1%) for peptide and protein identification. Label-free quantitation was employed with default 
settings. The UniProt database with ‘human’ entries (October 2017) was used for the database searches. Known 
contaminants as provided by MaxQuant and identified in the samples were excluded from further analysis, and 
Perseus software 1.6.1.3 was used for the statistical analysis of the total proteome MaxQuant results. Significant 
differentially expressed proteins were analyzed by the use of the principles of Gene Ontology (GO)75 that describe 
gene products in terms of their associated biological process, cellular component or molecular function, and we 
investigated the use of the protein/enzyme Kyoto Encyclopedia of Genes and Genomes (KEGG) database in the 
Functional Annotation Chart in the database for annotation, visualization and integrated discovery (DAVID). 
Heatmaps were generated based on the Z-scores (normalized with mean) of log10-transformed LFQ intensities by 
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pheatmap R package; pheatmap: Pretty Heatmaps. R package version 1.0.12. https ://CRAN.R-proje ct.org/packa 
ge=pheat map).
Immunohistochemistry and immunofluorescence. Four micron transverse sections of formalin-
fixed, paraffin-embedded mouse hearts and livers were deparaffinized in xylene, rehydrated in alcohol series and 
immersed in distilled water, followed by high-temperature antigen retrieval in citrate buffer (pH 6) and blocked 
with 1% bovine serum albumin (Sigma-Aldrich, St. Louis, MO, USA). Slides were stained with primary antibody 
against mouse anti-ceramide (1:100, Glycobiotech, Kuekels, Germany) and rat anti-mouse antibody against 
Mac-2 (1:1000, Cedarlane, Burlington, Canada), respectively, for 1 h at room temperature. After washing, slides 
were incubated for 30 min with biotinylated secondary antibody (goat anti-mouse IgM, Thermo Fisher Scien-
tific) and peroxidase-conjugated secondary antibody (goat anti-rat IgG, Thermo Fisher Scientific), respectively. 
After washing the slides were incubated in prepared Vectastain ABC kit (Vector Laboratories, Burlingame, CA, 
USA), rinsed and developed with chromogen for immunoperoxidase staining (DAB Plus, Vector Laboratories). 
The sections were counterstained with hematoxylin. Omission of the primary antibody was used as negative 
 control22. The stained sections were scanned (AxioScan Z1, Carl Zeiss, Oberkochen, Germany), and the amount 
of positive DAB-staining was quantitatively assessed using z9.uio.no, an in-house analysis application devised 
for whole slide images, by estimating cross sectional coverage of antibody expression within the tissue relative to 
the total area of the cross section of the tissue.
All histological analyses were performed blinded of genotype and treatment.
For immunofluorescence, the slides were stained with mouse anti-mouse antibody against ceramide (1:50, 
Glycobiotech); chicken anti-human antibody against Succinate dehydrogenase complex assembly factor 2, 
SDHAF2, a mitochondrial complex 2 marker (1:200, LSBio, Seattle, WA, USA); mouse anti-mouse antibody 
against NLRP3 (1:100, Adipogene, San Diego, CA, USA), rabbit anti-mouse against Caspase-1 p10 (1:100, Santa 
Cruz Biotechnology, Dallas, TX, USA) and Isolectin  IB4 Alexa Fluor 568 conjugate, an endothelial cell marker 
(Molecular Probes, Thermo Fisher Scientific) overnight at 4 °C and counterstained with Alexa Fluor 568 goat 
anti-mouse IgM; Alexa Fluor 488 goat anti-chicken IgY; Alexa Fluor 488 donkey anti-mouse IgG and Alexa Fluor 
488 goat anti-rabbit IgG, respectively. Images were captured using a Zeiss LSM710/Elyra S1 confocal microscope 
(Jena, Germany) housing a Plan-Apochromat W40x/1.0 DIC M27 objective. Zeiss ZEN Lite software or Adobe 
Photoshop was used for processing images. Omission of the primary antibody was used as a negative  control76. 
The stained sections were scanned (AxioScan Z1, Carl Zeiss), and the amount of positive fluorescent-staining 
was quantitatively assessed using z9.uio.no, as explained above.
Microbiota. Cecal content from 25 fasted mice was taken from the cecum with sterile equipment, and imme-
diately snap-frozen in liquid nitrogen and later stored at − 80 °C until DNA extraction (5–8 mice per treatment 
group). DNA from cecal content was extracted as previously  described77. In short, samples were resuspended in 
lysis buffer containing 20 mg/ml lysozyme (Sigma-Aldrich) and incubated at 37 °C for 30 min. Sodium dodecyl 
sulphate (10%, Sigma-Aldrich) and proteinase K (20 mg/ml, Qiagen, Chatsworth, CA, USA) were then added 
followed by 30 min incubation at 60  °C. The samples were then homogenized using a bead beater (BioSpec 
Products, Bartlesville, OK) and 300 mg zirconium beads (0.1 mm; BioSpec Products). Finally, samples were 
processed with DNeasy mini DNA extraction kit (Qiagen).
DNA libraries were prepared as described  elsewhere78. Briefly, libraries were generated from polymerase chain 
reaction (PCR) amplicons targeting the hypervariable regions V3 and V4 of the 16S ribosomal RNA gene, using 
dual-indexed universal primers 319F (forward) and 806R (reverse) along with Phusion High-Fidelity PCR Master 
Mix with HF buffer (Thermo Fisher Scientific). Cleaning and normalization of PCR products were performed 
using the SequalPrep Normalization Plate Kit (Thermo Fisher Scientific). Quality control and quantification of 
pooled libraries were performed using Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) and 
Kapa Library Quantification Kit (Kapa Biosystems Inc., Wilmington, MA, USA). Sequencing was performed at 
the Norwegian Sequencing Centre in Oslo, applying the Illumina MiSeq platform and v3 kit (Illumina, San Diego, 
CA, USA), allowing for 300-base pair paired-end reads. The genera Shewanella, Pseudomonas, Halomonas and 
Cutibacterium were detected in both negative controls, and were thus treated as contaminants and excluded from 
the dataset. To control for heterogeneous sequencing depths across the samples, all samples were rarefied to a 
level of 5789 reads. Calculations of alpha-diversity measures, as well as all subsequent analyses, were performed 
on this rarefied dataset using QIIME2.
ELISA, LPS binding protein. Mouse LPS binding protein (LBP) (ELISA kit, HycultBiotech, Weyne, PA, 
USA) was measured in plasma according to the manufacturer’s protocol.
Statistical analysis. One-way ANOVA was used to compare differences across the four experimental 
groups (GraphPad Prism version 8, GraphPad Software, La Jolla, CA, USA). Additionally, linear contrasts within 
ANOVA for specific comparisons of interest were performed (Welch’s two-sample t-test and two-sample t-test 
with pooled estimate of variance) for the metabolomics data. Student’s t-tests and Mann–Whitney U tests were 
conducted to compare the diversity between diet types. Scaled Imp Data: Each biochemical in OrigScale is 
rescaled to set the median equal to 1. Tables represent fold of change between  NLRP3−/− and WT mice on control 
diet or HFD; and between HFD and control diet in WT or  NLRP3−/− mice. Metabolite levels that increase in 
response to the diet are colored red (P ≤ 0.05), and lipid levels that decrease are colored green (P ≤ 0.05). Data of 
metagenomic analysis were analyzed using a least squares linear regression and Wilcoxon-test. Perseus software 
1.6.1.3 was used for the statistical analysis of total proteome data. Statistical significance for all data was set 
at P ≤ 0.05. Data are presented as mean ± standard error of the mean (SEM). # representing significant differences 
14
Vol:.(1234567890)
Scientific Reports |        (2020) 10:21006  | https://doi.org/10.1038/s41598-020-76497-1
www.nature.com/scientificreports/
between HFD and control diet within one genotype, (i.e. WT or  NLRP3−/−); and * representing significant differ-
ences between the two genotypes  (NLRP3−/− and WT) fed either HFD or control diet.
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